REGEN BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
REGEN BIOPHARMA, INC. (RGBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.74% for the 12-month period ending 2024-09-30, per its 8-K filed 2024-11-29.
Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-11-29
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-12-31 was 5.29%, a 35.99% increase year-over-year.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-12-31 was 3.89%, a 161.07% increase year-over-year.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-12-31 was 1.49%, a 14.86% decline year-over-year.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-12-31 was 1.75%, a 0.00% change year-over-year.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 5.29%, a 35.99% increase from fiscal 2022.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.89%, a 161.07% increase from fiscal 2021.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.49%, a 14.86% decline from fiscal 2020.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.75%, a 0.00% change from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-09-30 | 4.74% 8-K · filed 2024-11-29 | |||
| 2024-06-30 | 5.39% 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | 5.39% 10-Q · filed 2024-04-24 | |||
| 2023-12-31 | 5.29% 10-Q · filed 2024-01-19 | |||
| 2023-09-30 | 5.29% 10-K · filed 2023-11-20 | |||
| 2023-06-30 | 5.18% 10-Q · filed 2023-07-25 | |||
| 2023-03-31 | 3.48% 10-Q · filed 2023-04-18 | |||
| 2022-12-31 | 3.89% 10-Q · filed 2023-01-19 | |||
| 2022-09-30 | 3.89% 10-K · filed 2022-11-15 | |||
| 2022-06-30 | 2.98% 10-Q · filed 2022-07-22 | |||
| 2022-03-31 | 2.32% 10-Q · filed 2022-04-21 | |||
| 2021-12-31 | 1.49% 10-Q · filed 2022-01-20 | |||
| 2021-09-30 | 1.49% 10-K · filed 2021-12-22 | |||
| 2021-06-30 | 1.49% 10-Q/A · filed 2021-12-22 | |||
| 2021-03-31 | 1.75% 10-Q · filed 2021-08-18 | |||
| 2020-12-31 | 1.75% 10-Q · filed 2021-08-13 | |||
| 2020-09-30 | 1.75% 10-K · filed 2021-08-04 | |||
| 2020-06-30 | 1.75% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 1.75% 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 1.75% 10-Q · filed 2021-08-05 | |||
| 2019-09-30 | 1.75% 10-K · filed 2021-06-21 | |||
| 2019-06-30 | 2.14% 10-Q · filed 2019-10-24 | |||
| 2019-03-31 | 2.33% 10-Q · filed 2019-08-29 |